Random mutagenesis of β-tubulin defines a set of dispersed mutations that confer paclitaxel resistance

Pharmaceutical Research

Volumn 29, Issue 11, 2012, Pages 2994-3006

  Yin, Shanghua ^a   Zeng, Changqing ^a,b   Hari, Malathi ^a,c   Cabral, Fernando ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b Chinese Academy of Sciences and China National Center for Bioinformation   (China)

^c UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

cell division; drug resistance; microtubule assembly; mutant tubulin; neuronal disorders

Indexed keywords

BETA TUBULIN; COMPLEMENTARY DNA; PACLITAXEL;

ANIMAL CELL; ARTICLE; CANCER CELL CULTURE; CARCINOMA CELL; CHO CELL; CONTROLLED STUDY; DRUG RESISTANCE; FRACTIONATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE MICROSCOPY; MICROTUBULE; MITOSIS; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING; WILD TYPE;

ANIMALS; CELL LINE; CELL LINE, TUMOR; CHO CELLS; CRICETINAE; DEMECOLCINE; DRUG RESISTANCE, NEOPLASM; GIANT CELLS; HUMANS; MICROTUBULES; MITOSIS; MUTAGENESIS, SITE-DIRECTED; PACLITAXEL; POLYMERIZATION; TETRACYCLINE; TUBULIN;

EID: 84867858942     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0794-5     Document Type: Article

References (67)

1. Leandro-Garcia LJ, Leskela S, Landa I, Montero-Conde C, Lopez-Jimenez E, Leton R, et al. Tumoral and tissue-specific expression of the major human beta-tubulin isotypes. Cytoskeleton (Hoboken). 2010;67:214-23.
2. Luduena RF. Are tubulin isotypes functionally significant. Mol Biol Cell. 1993;4:445-57.
3. Ahmad S, Singh B, Gupta RS. Nucleotide sequences of three different isoforms of beta-tubulin cDNA from Chinese hamster ovary cells. Biochim Biophys Acta. 1991;1090:252-4.
4. Elliott EM, Henderson G, Sarangi F, Ling V. Complete sequence of three α-tubulin cDNAs in Chinese hamster ovary cells: each encodes a distinct α-tubulin isoprotein. Mol Cell Biol. 1986;6:906-13.
5. Sawada T, Cabral F. Expression and function of β-tubulin isotypes in Chinese hamster ovary cells. J Biol Chem. 1989;264:3013-20.
6. Risinger AL, Giles FJ, Mooberry SL. Microtubule dynamics as a target in oncology. Cancer Treat Rev. 2009;35:255-61.
7. Ravelli RBG, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, et al. Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature. 2004;428:198-202.
8. Gigant B, Wang C, Ravelli RBG, Roussi F, Steinmetz MO, Curmi PA, et al. Structural basis for the regulation of tubulin by vinblastine. Nature. 2005;435:519-22.
9. Downing KH. Structural basis for the interaction of tubulin with proteins and drugs that affect microtubule dynamics. Ann Rev Cell Dev Biol. 2000;16:89-111.
10. Nogales E, Whittaker M, Milligan RA, Downing KH. High-resolution model of the microtubule. Cell. 1999;96:79-88.
11. Begaye A, Trostel S, Zhao Z, Taylor RE, Schriemer DC, Sackett DL. Mutations in the beta-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding. Cell Cycle. 2011;10
12. Bennett MJ, Barakat K, Huzil JT, Tuszynski J, Schriemer DC. Discovery and characterization of the laulimalide-microtubule binding mode by mass shift perturbation mapping. Chem Biol. 2010;17:725-34.
13. Huzil JT, Chik JK, Slysz GW, Freedman H, Tuszynski J, Taylor RE, et al. A unique mode of microtubule stabilization induced by peloruside A. J Mol Biol. 2008;378:1016-30.
14. Kanakkanthara A, Wilmes A, O'Brate A, Escuin D, Chan A, Gjyrezi A, et al. Peloruside- and laulimalide-resistant human ovarian carcinoma cells have betaI-tubulin mutations and altered expression of betaII- and betaIII-tubulin isotypes. Mol Cancer Ther. 2011;10:1419-29.
15. Dumontet C, Jordan MA. Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov. 2010;9:790-803.
16. Berrieman HK, Lind MJ, Cawkwell L. Do beta-tubulin mutations have a role in resistance to chemotherapy? Lancet Oncol. 2004;5:158-64.
17. Yin S, Bhattacharya R, Cabral F. Human mutations that confer paclitaxel resistance. Mol Cancer Ther. 2010;9:327-35.
18. Cabral F. Mechanisms of resistance to drugs that interfere with microtubule assembly. In: Fojo AT, editor. Cancer drug discovery and development: The role of microtubules in cell biology, neurobiology, and oncology. Totowa: Humana Press; 2008. p. 337-56.
19. Cabral F. Factors determining cellular mechanisms of resistance to antimitotic drugs. Drug Resistance Updates. 2001;3:1-6.
20. Huzil JT, Chen K, Kurgan L, Tuszynski JA. The roles of beta-tubulin mutations and isotype expression in acquired drug resistance. Cancer Inform. 2007;3:159-81.
21. Gonzalez-Garay ML, Chang L, Blade K, Menick DR, Cabral F. A β-tubulin leucine cluster involved in microtubule assembly and paclitaxel resistance. J Biol Chem. 1999;274:23875-82.
22. Cabral F, Sobel ME, Gottesman MM. CHO mutants resistant to colchicine, colcemid or griseofulvin have an altered β-tubulin. Cell. 1980;20:29-36.
23. Minotti AM, Barlow SB, Cabral F. Resistance to antimitotic drugs in Chinese hamster ovary cells correlates with changes in the level of polymerized tubulin. J Biol Chem. 1991;266:3987-94.
24. Yang H, Ganguly A, Cabral F. Inhibition of cell migration and cell division correlates with distinct effects of microtubule inhibiting drugs. J Biol Chem. 2010;285:32242-50.
25. Schibler M, Cabral F. Taxol-dependent mutants of Chinese hamster ovary cells with alterations in α- and β-tubulin. J Cell Biol. 1986;102:1522-31.
26. Wang Y, Yin S, Blade K, Cooper G, Menick DR, Cabral F. Mutations at Leucine 215 of β-tubulin affect paclitaxel sensitivity by two distinct mechanisms. Biochemistry. 2006;45:185-94.
27. Giannakakou P, Gussio R, Nogales E, Downing KH, Zaharevitz D, Bollbuck B, et al. A common pharmacophore for epothilone and taxanes: molecular basis for drug resistance conferred by tubulin mutations in human cancer cells. Proc Natl Acad Sci USA. 2000;97:2904-9.
28. Giannakakou P, Sackett DL, Kang Y-K, Zhan Z, Buters JTM, Fojo T, et al. Paclitaxel-resistant human ovarian cancer cells have mutant β-tubulins that exhibit impaired paclitaxel-driven polymerization. J Biol Chem. 1997;272:17118-25.
29. Hara T, Ushio K, Nishiwaki M, Kouno J, Araki H, Hikichi Y, et al. A mutation in beta-tubulin and a sustained dependence on androgen receptor signalling in a newly established docetaxel-resistant prostate cancer cell line. Cell Biol Int. 2010;34:177-84.
30. Hari M, Loganzo F, Annable T, Tan X, Musto S, Morilla DB, et al. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules. Mol Cancer Ther. 2006;5:270-8.
31. He L, Yang CP, Horwitz SB. Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines. Mol Cancer Ther. 2001;1:3-10.
32. Mozzetti S, Iantomasi R, De Maria I, Prislei S, Mariani M, Camperchioli A, et al. Molecular mechanisms of patupilone resistance. Cancer Res. 2008;68:10197-204.
33. Verrills NM, Flemming CL, Liu M, Ivery MT, Cobon GS, Norris MD, et al. Microtubule alterations and mutations induced by desoxyepothilone B: implications for drug-target interactions. Chem Biol. 2003;10:597-607.
34. Yang CP, Verdier-Pinard P, Wang F, Lippaine-Horvath E, He L, Li D, et al. A highly epothilone B-resistant A549 cell line with mutations in tubulin that confer drug dependence. Mol Cancer Ther. 2005;4:987-95.
35. Blade K, Menick DR, Cabral F. Overexpression of class I, II, or IVb β-tubulin isotypes in CHO cells is insufficient to confer resistance to paclitaxel. J Cell Sci. 1999;112:2213-21.
36. Orr GA, Verdier-Pinard P, McDavid H, Horwitz SB. Mechanisms of Taxol resistance related to microtubules. Oncogene. 2003;22:7280-95.
37. Wang Y, Tian G, Cowan NJ, Cabral F. Mutations affecting β-tubulin folding and degradation. J Biol Chem. 2006;281:13628-35.
38. Bhattacharya R, Cabral F. A ubiquitous β-tubulin disrupts microtubule assembly and inhibits cell proliferation. Mol Biol Cell. 2004;15:3123-31.
39. Boggs B, Cabral F. Mutations affecting assembly and stability of tubulin: evidence for a non-essential β-tubulin in CHO cells. Mol Cell Biol. 1987;7:2700-7.
40. Cabral F, Abraham I, Gottesman MM. Isolation of a taxol-resistant Chinese hamster ovary cell mutant that has an alteration in α-tubulin. Proc Natl Acad Sci USA. 1981;78:4388-91.
41. Gonzalez-Garay ML, Cabral F. Overexpression of an epitope-tagged β-tubulin in Chinese hamster ovary cells causes an increase in endogenous α-tubulin synthesis. Cell Motil Cytoskeleton. 1995;31:259-72.
42. Yang H, Cabral F. Heightened sensitivity to paclitaxel in class IVa β-tubulin transfected cells is lost as expression increases. J Biol Chem. 2007;282:27058-66.
43. Gonzalez-Garay ML, Cabral F. α-tubulin limits its own synthesis: evidence for a mechanism involving translational repression. J Cell Biol. 1996;135:1525-34.
44. Abraham I, Marcus M, Cabral F, Gottesman MM. Mutations in α- and β-tubulin affect spindle formation in Chinese hamster ovary cells. J Cell Biol. 1983;97:1055-61.
45. Cabral F, Barlow SB. Resistance to antimitotic agents as genetic probes of microtubule structure and function. Pharmac Ther. 1991;52:159-71.
46. Kung AL, Sherwood SW, Schimke RT. Cell line-specific differences in the control of cell cycle progression in the absence of mitosis. Proc Natl Acad Sci USA. 1990;87:9553-7.
47. Cabral F. Isolation of Chinese hamster ovary cell mutants requiring the continuous presence of taxol for cell division. J Cell Biol. 1983;97:22-9.
48. Cabral F, Wible L, Brenner S, Brinkley BR. Taxol-requiring mutant of Chinese hamster ovary cells with impaired mitotic spindle assembly. J Cell Biol. 1983;97:30-9.
49. Cabral F, Brady RC, Schibler MJ. A mechanism of cellular resistance to drugs that interfere with microtubule assembly. Ann NY Acad Sci. 1986;466:745-56.
50. Ganguly A, Yang H, Cabral F. Paclitaxel dependent cell lines reveal a novel drug activity. Mol Cancer Ther. 2010;9:2914-23.
51. Ganguly A, Cabral F. New insights into mechanisms of resistance to microtubule inhibitors. Biochim Biophys Acta. 2011;1816:164-71.
52. Yin S, Cabral F, Veeraraghavan S. Amino acid substitutions at proline 220 of β-tubulin confer resistance to paclitaxel and colcemid. Mol Cancer Ther. 2007;6:2798-806.
53. Tischfield MA, Cederquist GY, Gupta MLJ, Engle EC. Phenotypic spectrum of the tubulin-related disorders and functional implications of disease-causing mutations. Curr Opin Genet Dev. 2011;21:286-94.
54. Luduena RF. Multiple forms of tubulin: different gene products and covalent modifications. Internatl Rev Cytol. 1998;178:207-75.
55. DeLano WL. MacPyMOL: A PyMOL-based molecular graphics application for MacOS X. South San Francisco: DeLano Scientific LLC; 2005.
56. Lowe J, Li H, Downing KH, Nogales E. Refined structure of αβ-tubulin at 3.5 A resolution. J Mol Biol. 2001;313:1045-57.
57. Wang Y, Veeraraghavan S, Cabral F. Intra-allelic suppression of a mutation that stabilizes microtubules and confers resistance to colcemid. Biochemistry. 2004;43:8965-73.
58. Jaglin XH, Poirier K, Saillour Y, Buhler E, Tian G, Bahi-Buisson N, et al. Mutations in the beta-tubulin gene TUBB2B result in asymmetrical polymicrogyria. Nat Genet. 2009;41:746-52.
59. Poruchynsky MS, Kim JH, Nogales E, Annable T, Loganzo F, Greenberger LM, et al. Tumor cells resistant to a microtubule-depolymerizing hemiasterlin analogue, HTI-286, have mutations in alpha- or beta-tubulin and increased microtubule stability. Biochemistry. 2004;43:13944-54.
60. Poirier K, Saillour Y, Bahi-Buisson N, Jaglin XH, Fallet-Bianco C, Nabbout R, et al. Mutations in the neuronal β-tubulin subunit TUBB3 result in malformation of cortical development and neuronal migration defects. Hum Mol Genet. 2010;19:4462-73.
61. Gokmen-Polar Y, Escuin D, Walls CD, Soule SE, Wang Y, Sanders KL, et al. beta-Tubulin mutations are associated with resistance to 2-methoxyestradiol in MDA-MB-435 cancer cells. Cancer Res. 2005;65:9406-14.
62. Liaw TY, Salam NK, McKay MJ, Cunningham AM, Hibbs DE, Kavallaris M. Class I beta-tubulin mutations in 2-methoxyestradiol-resistant acute lymphoblastic leukemia cells: implications for drug-target interactions. Mol Cancer Ther. 2008;7:3150-9.
63. Hari M, Wang Y, Veeraraghavan S, Cabral F. Mutations in α- and β-tubulin that stabilize microtubules and confer resistance to colcemid and vinblastine. Mol Cancer Ther. 2003;2:597-605.
64. Hua XH, Genini D, Gussio R, Tawatao R, Shih H, Kipps TJ, et al. Biochemical genetic analysis of indanocine resistance in human leukemia. Cancer Res. 2001;61:7248-54.
65. Lee VD, Huang B. Missense mutations at lysine 350 in beta 2-tubulin confer altered sensitivity to microtubule inhibitors in Chlamydomonas. Plant Cell. 1990;2:1051-7.
66. Bhattacharya R, Cabral F. Molecular basis for class V β-tubulin effects on microtubule assembly and paclitaxel resistance. J Biol Chem. 2009;284:13023-32.
67. Cheung CH, Wu SY, Lee TR, Chang CY, Wu JS, Hsieh HP, et al. Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes. PLoS One. 2010;5:e12564.